ACEA Therapeutics

ACEA Therapeutics, located in San Diego, California is a wholly owned subsidiary of Sorrento. ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases.

Our lead compound, Abivertinib, a small molecule kinase inhibitor, is currently under review by the China Food and Drug Administration (CFDA) for the treatment of patients with non-small cell lung cancer (NSCLC) containing the EGFR T790M mutation. It is also in clinical trials to treat hospitalized patients with Covid-19 in Brazil and US led by Sorrento Therapeutics. A second small molecule kinase inhibitor of ACEA, AC0058, has entered Phase 1B development in the US for the treatment of systemic lupus erythematosus (SLE).

Alongside a robust R&D organization, ACEA has established drug manufacturing and commercial capabilities in China to support our long-term growth. This infrastructure provides us greater control over our supply chain to make sure products are delivered to patients on-time.